Follow RSS for latest reports on this topicRemicade (Infliximab) - Market Research and Reports

Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn's Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines

2012 sales: $8.215 billion [ $6.139 billion J&J + $2.076 billion Merck & Co.]

Drug maker: Johnson & Johnson and Merck & Co.

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...

or can supply a pro-forma invoice if required.

Related Reports:

We found 3 reports that matched your search.

Refine your search, and find more matches, using the form above.

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021) [Report Updated: 14-09-2016]

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population are the prime growth drivers of global remicade biosimilar market. In addition, increase in adoption of remicade biosimilar in emerging ...Read More >>>


Published by: Industry ARC

Prices Starting From:

Additional Searches

You may also like to search separately for: Remicade (Infliximab)

We Stock...